NEW YORK, Oct. 14, 2015 /PRNewswire/ -- Bronstein,
Gewirtz & Grossman, LLC reminds investors that a securities
class action has been filed in the United States District Court for
the District of Maryland on behalf
of those who purchased securities of Northwest
Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the
"Company") (NasdaqCM: NWBO), during the period between March 8, 2013 and August
20, 2015 inclusive. (the "Class Period").
The Complaint alleges that throughout the Class Period,
Defendants made false and/or misleading statements, as well as
failed to disclose material adverse facts about the Company's
business, operations, and prospects. Specifically, Defendants made
false and/or misleading statements and/or failed to disclose that:
(i) the Company's claims regarding positive results from its
DCVax-Direct Trial were based on preliminary and unconfirmed trial
results; (ii) the DCVax-Direct Trial results on which the Company
reported had not been reviewed or analyzed by the hospitals
conducting the trials; (iii) the Company's statements about
DCVax-Direct were derived from patient case report forms, which the
hospitals were obliged to send to the Company only because it
sponsored the study; (iv) the Company was the subject of an
aggressive stock promotion campaign which included promoters using
fictitious identities and false credentials; (v) German regulators
required additional information from the Company in order for the
Company's DCVax-L Trial to continue uninterrupted; and (vi) as a
result of the above, the Company's financial statements were
materially false and misleading at all relevant times.
No Class has yet been certified in the above action. If you wish
to review a copy of the Complaint, to discuss this action, or have
any questions, please contact Peretz
Bronstein, Esq. or his Investor Relations Coordinator
Eitan Kimelman of Bronstein, Gewirtz
& Grossman, LLC at 212-697-6484 or via email info@bgandg.com.
Those who inquire by e-mail are encouraged to include their mailing
address and telephone number. If you suffered a loss in
Northwest Biotherapeutics you have until October 26, 2015 to request that the Court
appoint you as lead plaintiff. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-reminds-investors-of-class-action-against-northwest-biotherapeutics-inc-and-lead-plaintiff-deadline-october-26-2015-300158963.html
SOURCE Bronstein, Gewirtz & Grossman, LLC